Monday 4 October

Tuesday 5 October

 

Opening lecture: Physiological Pathway to Frailty

L. Ferrucci

N.A

 

Opening lecture: Clinical Epidemiology of Frailty

J. Margolick

Pres.

 

 

Session 1: Immunology

Invited lecture: Immunology of Agingy

A. Landay

N.A

 

Accelerated cellular senescence of plasmacytoid dendritic cells in HIV-infected patients

J. Dai

N.A

 

T-cell immunosenescence is associated with the presence of Kaposi’s sarcoma in antiretroviral treated human immunodeficiency virus infected persons

P. Unemori

Pres.

 

 

Session 2: Neurology

Invited lecture: Neurocognitive changes in aging with HIV infection: Pathophysiological mechanisms

A. Nath

N.A

 

Genome-wide analysis of CNS gene expression in transgenic mice expressing HIV gp120 in the brain reveals alterations depending on genotype and age

M. Kaul

N.A

 

Higher levels of phosphorylated tau in CSF are associated with HIV infection, older age, antiretroviral use, and worse prospective memory

S. Letendre

Pres.

 

Novel biomarkers for neurological disorders associated with HIV/aging from the SIV/macaque model

K. Witwer

Pres.

 

 

Session 3: Musculoskeletal Disease

Invited lecture: Osteoporosis in the older HIV-infected patient

T. Brown

Pres.

 

invited lecture: Vitamin D deficiency and HIV Infection: adding insult to injury

J. Currier

Pres.

 

Association of Vitamin D deficiency with lipoatrophy amongst HIV positive patients in Windsor Ontario

L. Robinson

Pres.

 

Age-stratified risk assessment for fracture among adults with and without HIV infection

L. Mundy

Pres.

 

 

Session 4: Pharmacology

Invited lecture: Effect of Aging on Human Pharmacology

J. Schwartz

N.A

 

Polypharmacy in older patients: a study of medication use and potential drug interactions in an aging ambulatory HIV clinic population

A. Tseng

N.A

 

Polypharmacology for polypathology in HIV infected patients

G. Guaraldi

Pres.

 

 

 

Effect of age on baseline CD4+ cells and immunologic response to regimens with or without Maraviroc

H. Valdez

Pres.

 

Effect of age on baseline CD4+and CD8+ cells and response to Antiretroviral Therapy (ART) over 48 weeks in a large clinical trial database

J. Demarest

Pres.

 

Low risk of malignancy in Maraviroc (MVC) treated patients in the MVC clinical development program is preserved in older age groups.

S. Portsmouth

Pres.

 

Comorbidities and co-infections among HIV patients 50 years and older

E. Nkhoma

Pres.

 

 

Virology Education -
a Medical Education company